| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing-Hang Xu, Sa Wang, Da-Zhi Zhang, Yan-Yan Yu, Chong-Wen Si, Zheng Zeng, Zhong-Nan Xu, Jun Li, Qing Mao, Hong Tang, Ji-Fang Sheng, Xin-Yue Chen, Qin Ning, Guang-Feng Shi, Qing Xie, Xi-Quan Zhang and Jun Dai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yan-Yan Yu, Doctor, MD, PhD, Doctor, Professor, Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100094, China. yyy@bjmu.edu.cn |
| Key Words |
Chronic hepatitis B; Entecavir maleate; Randomized controlled trial; Treatment outcome; Mutation; Genotype |
| Core Tip |
This randomized, double-blind, double-dummy, controlled, multicenter trial showed that long-term treatment with entecavir (ETV) maleate provides safe, potent and reliable suppression of HBV replication for 192 wk in Chinese chronic hepatitis B patients predominantly genotyped as B or C with little chance of developing ETV-resistant mutations. |
| Publish Date |
2022-09-27 13:00 |
| Citation |
Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i28.10085 |
